Literature DB >> 31286344

Overexpression of TIPE2, a Negative Regulator of Innate and Adaptive Immunity, Attenuates Cognitive Deficits in APP/PS1 Mice.

Yongzhen Miao1, Naidong Wang2, Wenjin Shao3, Zihan Xu1, Zhihong Yang1, Lei Wang1, Chuanxia Ju1, Ruoyu Zhang1, Fang Zhang4.   

Abstract

Neuroinflammation plays an early and prominent role in the pathology of Alzheimer's disease (AD). Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2) has been identified as a negative regulator of innate and adaptive immunity. However, whether TIPE2 affects cognitive functions in AD-like mouse models remains unknown. In this study, we compared the gene and protein expressions of TIPE2 between the APP/PS1 mice and the age-matched wild type (WT) mice at different stages of development using western blot and RT-qPCR. The hippocampal expression of the TIPE2 mRNA and protein in APP/PS1 mice was higher than that of the WT mice starting from 6 months to 10 months. However, the difference of the TIPE2 expression between the APP/PS1 mice and the WT mice declined in a time-dependent manner. The spatial learning and memory deficit from the 8-month-old APP/PS1 mice was observed in the Y-maze test and fear conditioning task. Interestingly, overexpression of TIPE2 by intra-hippocampal injection of AAV-TIPE2 into APP/PS1 mice resulted in an improvement of learning and memory and reduced expression of inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, and increased expression of anti-inflammatory cytokines, such as IL-10 and Arg-1. Taken together, our findings show that the TIPE2 expression level was negatively correlated with the pathogenesis of Alzheimer's disease, and overexpression of TIPE2 attenuates cognitive deficits in APP/PS1 mice, suggesting TIPE2 is a potential target for pharmacological intervention and improvement of cognitive deficits. Graphical Abstract .

Entities:  

Keywords:  APP/PS1 transgenic mice; Alzheimer’s disease; Hippocampus; TIPE2; Y-maze

Mesh:

Substances:

Year:  2019        PMID: 31286344     DOI: 10.1007/s11481-019-09861-2

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  26 in total

Review 1.  Changing face of microglia.

Authors:  Manuel B Graeber
Journal:  Science       Date:  2010-11-05       Impact factor: 47.728

2.  Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.

Authors:  Ana Griciuc; Alberto Serrano-Pozo; Antonio R Parrado; Andrea N Lesinski; Caroline N Asselin; Kristina Mullin; Basavaraj Hooli; Se Hoon Choi; Bradley T Hyman; Rudolph E Tanzi
Journal:  Neuron       Date:  2013-04-25       Impact factor: 17.173

3.  Simple colour reaction for alkaptonuria.

Authors:  K Valmikinathan; N Verghese
Journal:  J Clin Pathol       Date:  1966-03       Impact factor: 3.411

Review 4.  Microglia Function in the Central Nervous System During Health and Neurodegeneration.

Authors:  Marco Colonna; Oleg Butovsky
Journal:  Annu Rev Immunol       Date:  2017-02-09       Impact factor: 28.527

5.  Blockage of CR1 prevents activation of rodent microglia.

Authors:  Helen Crehan; John Hardy; Jennifer Pocock
Journal:  Neurobiol Dis       Date:  2013-02-27       Impact factor: 5.996

6.  Biology of Microglia in the Developing Brain.

Authors:  Charanjit Kaur; Gurugirijha Rathnasamy; Eng-Ang Ling
Journal:  J Neuropathol Exp Neurol       Date:  2017-09-01       Impact factor: 3.685

7.  Enhanced contextual fear memory in central serotonin-deficient mice.

Authors:  Jin-Xia Dai; Hui-Li Han; Meng Tian; Jun Cao; Jian-Bo Xiu; Ning-Ning Song; Ying Huang; Tian-Le Xu; Yu-Qiang Ding; Lin Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-11       Impact factor: 11.205

8.  CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology.

Authors:  Elizabeth M Bradshaw; Lori B Chibnik; Brendan T Keenan; Linda Ottoboni; Towfique Raj; Anna Tang; Laura L Rosenkrantz; Selina Imboywa; Michelle Lee; Alina Von Korff; Martha C Morris; Denis A Evans; Keith Johnson; Reisa A Sperling; Julie A Schneider; David A Bennett; Philip L De Jager
Journal:  Nat Neurosci       Date:  2013-05-23       Impact factor: 24.884

9.  Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD.

Authors:  Carol A Colton; Ryan T Mott; Hayley Sharpe; Qing Xu; William E Van Nostrand; Michael P Vitek
Journal:  J Neuroinflammation       Date:  2006-09-27       Impact factor: 8.322

10.  TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models.

Authors:  Taylor R Jay; Crystal M Miller; Paul J Cheng; Leah C Graham; Shane Bemiller; Margaret L Broihier; Guixiang Xu; Daniel Margevicius; J Colleen Karlo; Gregory L Sousa; Anne C Cotleur; Oleg Butovsky; Lynn Bekris; Susan M Staugaitis; James B Leverenz; Sanjay W Pimplikar; Gary E Landreth; Gareth R Howell; Richard M Ransohoff; Bruce T Lamb
Journal:  J Exp Med       Date:  2015-03-02       Impact factor: 14.307

View more
  2 in total

1.  Impaired Learning and Memory Ability Induced by a Bilaterally Hippocampal Injection of Streptozotocin in Mice: Involved With the Adaptive Changes of Synaptic Plasticity.

Authors:  Cong-Cong Qi; Xing-Xing Chen; Xin-Ran Gao; Jing-Xian Xu; Sen Liu; Jin-Fang Ge
Journal:  Front Aging Neurosci       Date:  2021-03-01       Impact factor: 5.750

2.  Interaction between TRPML1 and p62 in Regulating Autophagosome-Lysosome Fusion and Impeding Neuroaxonal Dystrophy in Alzheimer's Disease.

Authors:  Lu Zhang; Yu Fang; Xuan Cheng; Yajun Lian; Hongliang Xu
Journal:  Oxid Med Cell Longev       Date:  2022-01-25       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.